{"id":"NCT00303316","sponsor":"Sanofi","briefTitle":"Immunogenicity Study of Antibody Persistence and Booster Effect of PENTAXIM™ at 18 Months in Healthy Argentinean Infants","officialTitle":"Immunogenicity Study of the Antibody Persistence and Booster Effect of PENTAXIM™ at 18 Months of Age Following a Primary Series of DTaP-IPV-HB-PRP~T Combined Vaccine or of PENTAXIM™ and ENGERIX B® PEDIATRICO at 2, 4, and 6 Months of Age in Healthy Argentinean Infants","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-02","primaryCompletion":"2007-04","completion":"2007-09","firstPosted":"2006-03-16","resultsPosted":"2013-02-22","lastUpdate":"2013-02-22"},"enrollment":458,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Diphtheria","Tetanus","Pertussis","Poliomyelitis","Hepatitis B"],"interventions":[{"type":"BIOLOGICAL","name":"DTaP-IPV//PRP~T combined vaccine","otherNames":["PENTAXIM™"]},{"type":"BIOLOGICAL","name":"DTaP-IPV//PRP~T combined vaccine","otherNames":["PENTAXIM™"]}],"arms":[{"label":"DTacP IPV HepB PRP-T Combined Vaccine Group","type":"EXPERIMENTAL"},{"label":"PENTAXIM™ and ENGERIX B® Vaccine Group","type":"ACTIVE_COMPARATOR"}],"summary":"This study will assess both the antibody persistence of the investigational vaccine and the immune response and safety of a booster dose of PENTAXIM™ vaccine in 18 months-old toddlers who participated in an earlier study in order to determine if they are still protected before they receive a booster dose of D, T, IPV, pertussis or Hib vaccines and also to assess the quality of the induced immune memory in response to a booster dose of the same vaccine as in the primary series.\n\nPrimary Objective:\n\nTo describe the antibody persistence at 18 months of age and the booster effect of a dose of PENTAXIM™ on immunogenicity.\n\nSecondary objective:\n\nTo describe the safety profile of the booster dose PENTAXIM™ in each vaccine group defined by the vaccines received during the primary series.","primaryOutcome":{"measure":"Summary of Antibody Persistence at 18 Months of Age in Participants That Received Primary Series Vaccination of Either DTaP-IPV-HepB-PRP~T or PENTAXIM™ and ENGERIX B® PEDIATRICO at 2, 4, and 6 Months of Age.","timeFrame":"Day 0 (Before booster vaccination)","effectByArm":[{"arm":"DTacP-IPV-Hep B-PRP~T Group","deltaMin":195,"sd":null},{"arm":"PENTAXIM™ and ENGERIX B® Group","deltaMin":221,"sd":null}],"pValues":[]},"eligibility":{"minAge":"510 Days","sex":"ALL","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":17},"locations":{"siteCount":1,"countries":["Argentina"]},"refs":{"pmids":["22157567"],"seeAlso":["http://www.sanofipasteur.com"]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":231},"commonTop":["Solicited Injection Site Pain","Irritability","Solicited Injection Site Erythema","Solicited Injection Site Swelling","Crying"]}}